Clinical Trials

Regeneron

IRB
Details
Info
EMC-IRB-24-030
A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma.